# OnCo record febrile-neutropenia (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/febrile-neutropenia/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "febrile-neutropenia" ;
  schema:name "Febrile neutropenia"@en ;
  schema:alternateName "neutropenic fever"@en, "neutropenic sepsis"@en, "febrile neutropaenia"@en, "FN rate"@en, "neutropenic infection"@en, "infection during neutropenia"@en ;
  schema:description "Fever in a patient whose infection-fighting white cells have been wiped out by chemotherapy. It is a medical emergency: without immune cells, an ordinary infection can become fatal in hours, so antibiotics are started immediately."@en ;
  schema:url <https://onco.cc/terms/febrile-neutropenia/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Febrile_neutropenia> ;
  schema:citation <https://en.wikipedia.org/wiki/Febrile_neutropenia>, <https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/sepsis>, <https://www.nhs.uk/conditions/sepsis/>, <https://www.nice.org.uk/guidance/cg151>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/neutropenia-low-neutrophils> ;
  onco:related <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/dose-limiting-toxicity/>, <https://onco.cc/terms/dose-modification/>, <https://onco.cc/terms/cytopenias/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/malt-lymphoma/>, <https://onco.cc/cancers/splenic-marginal-zone-lymphoma/>, <https://onco.cc/cancers/nodal-marginal-zone-lymphoma/>, <https://onco.cc/cancers/waldenstrom/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/>, <https://onco.cc/cancers/burkitt-lymphoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/>, <https://onco.cc/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/angioimmunoblastic-t-cell-lymphoma/>, <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/>, <https://onco.cc/cancers/sezary-syndrome/>, <https://onco.cc/cancers/primary-cns-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/g-csf-growth-factors/> .